E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Diabetes Mellitus, Type 1 |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10045228 |
E.1.2 | Term | Type I diabetes mellitus |
E.1.2 | System Organ Class | 100000004861 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to evaluate the effect of NNC0114-0006, liraglutide and the combination of NNC0114 0006 and liraglutide, compared to placebo, on preservation of beta-cell function after 54 weeks of treatment in adult subjects with newly diagnosed type 1 diabetes mellitus (T1DM) |
|
E.2.2 | Secondary objectives of the trial |
Objectives related to treatment period (from baseline (week 0) to week 54):
- To assess safety and tolerability of NNC0114-0006 and liraglutide in combination and alone in subjects with newly diagnosed T1DM
- To assess effect on glycaemic parameters (including insulin usage and insulin regimen) of NNC0114-0006 and liraglutide in combination and alone in subjects with newly diagnosed T1DM
Objectives related to the post-treatment observation period (from week 54 to week 80):
- To assess post-treatment safety and tolerability of NNC0114-0006 and liraglutide in combination and alone in subjects with newly diagnosed T1DM
- To assess post-treatment effect on preservation of beta-cell function of NNC0114-0006 and liraglutide in combination and alone in subjects with newly diagnosed T1DM
- To assess post-treatment effect on glycaemic parameters (including insulin usage and insulin regimen) of NNC0114-0006 and liraglutide in combination and alone in subjects with newly diagnosed T1DM
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial
2. T1DM (as diagnosed clinically*) ≤ 20 weeks prior to screening
3. Male or female, aged 18-45 (both inclusive) at the time of signing the informed consent form
4. Non-fasting peak C-peptide ≥0.2 nmol/l during MMTT at Visit 2
5. BMI ≥18.5 kg/m^2
6. Presence of one or more islet specific auto antibodies (glutamic acid decarboxylase (GAD), islet antigen-2 (IA2) or zinc-transporter 8 (ZnT8)) at screening
7. Insulin dependence unless in temporary spontaneous remission (honeymoon period).
*The clinical diagnosis of T1DM is defined as by the following two paragraphs:
1. One or more of the following:
- HbA1c ≥ 6.5% or
- fasting plasma glucose ≥ 7.0 mmol/l (126 mg/dl) or
- a 2 hour plasma glucose ≥ 11.1 mmol/l (200 mg/dl) during an oral glucose tolerance test
with a glucose load of 75 grams anhydrous glucose in water or
- classical symptoms of hyperglycaemia and a random plasma glucose ≥ 11.1 mmol/l (200
mg/dl)
In the absence of unequivocal hyperglycaemia, results should be confirmed by repeat testing.
2. In order to:
- ensure that the aetiology is autoimmune, the clinical diagnosis needs to be confirmed by the presence of islet-specific auto-antibodies at screening
- exclude type 2 diabetes mellitus (T2DM) and latent autoimmune diabetes of adults (LADA) the subjects should be without severe insulin resistance (i.e. total daily insulin dose larger than 1 U/kg per day at screening). |
|
E.4 | Principal exclusion criteria |
1. Daily insulin usage > 1 U/kg per day at screening or use of continuous subcutaneous insulin infusion (CSII)
2. History of recurrent (e.g. several times a year) of severe (e.g. pneumonia) or chronic infections or conditions predisposing to chronic infections (e.g., bronchiectasis and chronic osteomyelitis)
3. History of severe systemic fungal infection within the past 12 months prior to screening unless treated and resolved with appropriate documented therapy
4. Vaccination within 4 weeks before randomisation, Visit 3 (V3)
5. Receipt of any other concomitant medications or herbal products that can influence the immune system within 90 days prior to screening (V1)
6. History of pancreatitis (acute or chronic)
7. Family or personal history of Multiple Endocrine Neoplasia Type 2 (MEN2) or Medullary Thyroid Carcinoma (MTC)
8. Any past or current diagnosis of malignant neoplasms
9. Known impairment of the immune system, except for T1DM, coeliac disease, alopecia, autoimmune antibodies not considered clinical important (e.g. thyroid antibodies without any clinically important thyroid disease), and vitiligo |
|
E.5 End points |
E.5.1 | Primary end point(s) |
AUC0-4h, C-peptide, 54w/AUC0-4h, C-peptide, baseline: AUC0-4h for a mixed meal tolerance test (MMTT) stimulated C-peptide concentration-time curve |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At week 54 relative to baseline (defined as the MMTT performed at Visit 2) |
|
E.5.2 | Secondary end point(s) |
1. Number of treatment emergent episodes of diabetic ketoacidosis (DKA)
2. Number of treatment emergent hypoglycaemic episodes according to the American Diabetes Association (ADA) and Novo Nordisk definitions
3. AUC0-4h for MMTT stimulated C-peptide concentration time curve
4. AUC0-2h for MMTT stimulated C-peptide concentration time curve
5. Maximum MMTT stimulated C-peptide concentration (Cmax, C-peptide)
6. Change in fasting C-peptide
7. Change in HbA1c
8. Change in fasting plasma glucose
9. Total daily insulin dose in units per kg (three day average) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. From first dose of trial product to week 54
2. From first dose of trial product to week 54
3. At week 80 relative to baseline
4. At week 54 and week 80 relative to baseline
5. At week 54 and week 80 relative to baseline
6. From baseline to week 54 and week 80
7. From baseline to week 54 and week 80
8. From baseline to week 54 and week 80
9. At week 54 and week 80
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Clinical proof of principle; tolerability |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 44 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
European Union |
Israel |
Russian Federation |
Ukraine |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | 25 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 17 |